Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 235Breast Neoplasms 233Prostatic Neoplasms 170Multiple Myeloma 151Neoplasms 134Colorectal Neoplasms 126Leukemia, Myeloid, Acute 121Lung Neoplasms 108Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 88Melanoma 86Lymphoma 82Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 71Sarcoma 68Carcinoma, Renal Cell 64Recurrence 63Lymphoma, Large B-Cell, Diffuse 63Brain Neoplasms 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 57Lymphoma, Non-Hodgkin 56Stomach Neoplasms 54Leukemia, Lymphocytic, Chronic, B-Cell 54Endometrial Neoplasms 53Hematologic Neoplasms 52Urinary Bladder Neoplasms 50Small Cell Lung Carcinoma 49

Interventions

Hizentra 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Common Variable Immunodeficiency × 90 days × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡